How can the EU’s pharmaceutical legislation help tackle current challenges, including medicine shortages and antimicrobial resistance, across Europe? We put the question to Rainer Becker, Director for Medical Products and Innovation at DG SANTE.
A second groundbreaking drug for Alzheimer's disease has been rejected for widespread use by the NHS in England; according to the drugs spending watchdog, the drug known as Donanemab does not offer sufficient value for money.
In a concerted effort to combat the alarming issue of fatal drug deaths across the UK, the government has allocated £5 million to support 12 groundbreaking projects.
In a surprising turn of events, Prince Harry's public endorsement of the transformative power of psychedelic therapy has triggered a psychedelic resurgence in the UK.
Despite the rising incidence of Central Nervous System diseases worldwide, efficient treatment options for neurological disorders remain scarce. Treatment failures are principally associated with the inability of drugs to pass the highly selective Blood-Brain Barrier rather than a lack of efficacy.
World Health Organization, Regional Office for the Eastern Mediterranean, describes what we need to know about osteoporosis prevention, management and treatment, an integral component of their vision for healthy ageing.
Cannabis legislation is threatening to reduce pharmaceutical stock value by billions of dollars as more people are predicted to opt for weed over opioids.
